Document is current
Any future updates will be listed below
-
Authors
Andtbacka, Robert H. I.
Collichio, Frances
Harrington, Kevin J.
Middleton, Mark R.
Downey, Gerald
Ӧhrling, Katarina
Kaufman, Howard L.
-
Funding
Funding for this research was provided by:
Amgen Inc
- License Information
-
More Information
Article History
Received: 4 December 2018
Accepted: 17 May 2019
First Online: 6 June 2019
Ethics approval and consent to participate
: Study procedures were approved by the institutional review boards or ethics committees for each participating site, and all patients provided written informed consent.
: Not applicable.
: Andtbacka RHI – is an employee of Birdie Pharmaceuticals and has received fees for consultation or other remuneration from Amgen and Merck; Collichio F – her institution is receiving research support from Amgen, Novartis, and Merck; Harrington K – has received consulting or advisory fees from Amgen, AstraZeneca, BMS, Merck, and Pfizer; his institution has received research grants from AstraZeneca and MSD; has served on speaker bureaus for Amgen, AstraZeneca, BMS, Merck, and MSD; Middleton M – has acted as a consultant for Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Immunocore, Lilly, Merck, Millennium, Novartis, Physiomics, Rigontec, and Roche; his institution has received research grants from Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, Eisai, GlaxoSmithKline, Immunocore, Merck, Millennium, Novartis, Pfizer, Rigontec, Roche, and Vertex; Downey G – former employee of Amgen; Ӧhrling K – employee and stock holder of Amgen; Kaufman HL – is an employee of Replimune, Inc. and has served on advisory board for SapVax.
